Evidence map›Paper›PMID 22530008›Full record

ArticlePloS one2012

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.

James J Kobie, Danielle C Alcena, Bo Zheng, Peter Bryk, Jonelle L Mattiacio, Matthew Brewer, Celia Labranche, Faith M Young, Stephen Dewhurst, David C Montefiori and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

James J KobieDivision of Allergy, University of Rochester Medical Center, Rochester, New York, United States of America. james_kobie@urmc.rochester.edu
Danielle C Alcena
Bo Zheng
Peter Bryk
Jonelle L Mattiacio
Matthew Brewer
Celia Labranche
Faith M Young
Stephen Dewhurst
David C Montefiori
Alexander F Rosenberg
Changyong Feng
Xia Jin
Michael C Keefer
Ignacio Sanz
University of Rochester Medical Center · USDuke Medical Center · USDuke University Hospital · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
Training in HIV Replication and PathogenesisT32AI049815 · NIAID · UNIVERSITY OF ROCHESTER · PI WEDEKIND, JOSEPH E · 2001 to 2020
$3.5M
Understanding the Generation of HIV Broadly Neutralizing AntibodiesR01AI084808 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2009 to 2013
$3.2M
Cellular Origins of HIV Broadly Neutralizing AntibodiesR21AI078459 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2008 to 2009
$535k
NIAID NIH HHS 5P30AI027757NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI084808NIAID NIH HHS R01AI084808NIAID NIH HHS R21 AI078459NIAID NIH HHS R21AI078459NIAID NIH HHS R37 AI049660NIAID NIH HHS R37AI049660NIAID NIH HHS T32 AI049815NIAID NIH HHS UM1 AI068614
6 · The paper itself

Abstract

The induction of a broadly neutralizing antibody (BNAb) response against HIV-1 would be a desirable feature of a protective vaccine. Vaccine strategies thus far have failed to elicit broadly neutralizing antibody responses; however a minority of HIV-infected patients do develop circulating BNAbs, from which several potent broadly neutralizing monoclonal antibodies (mAbs) have been isolated. The findings that several BNmAbs exhibit autoreactivity and that autoreactive serum antibodies are observed in some HIV patients have advanced the possibility that enforcement of self-tolerance may contribute to the rarity of BNAbs. To examine the possible breakdown of tolerance in HIV patients, we utilized the 9G4 anti-idiotype antibody system, enabling resolution of both autoreactive VH4-34 gene-expressing B cells and serum antibodies. Compared with healthy controls, HIV patients had significantly elevated 9G4+ serum IgG antibody concentrations and frequencies of 9G4+ B cells, a finding characteristic of systemic lupus erythematosus (SLE) patients, both of which positively correlated with HIV viral load. Compared to the global 9G4-IgD--memory B cell population, the 9G4+IgD--memory fraction in HIV patients was dominated by isotype switched IgG+ B cells, but had a more prominent bias toward "IgM only" memory. HIV envelope reactivity was observed both in the 9G4+ serum antibody and 9G4+ B cell population. 9G4+ IgG serum antibody levels positively correlated (r = 0.403, p = 0.0019) with the serum HIV BNAbs. Interestingly, other serum autoantibodies commonly found in SLE (anti-dsDNA, ANA, anti-CL) did not correlate with serum HIV BNAbs. 9G4-associated autoreactivity is preferentially expanded in chronic HIV infection as compared to other SLE autoreactivities. Therefore, the 9G4 system provides an effective tool to examine autoreactivity in HIV patients. Our results suggest that the development of HIV BNAbs is not merely a consequence of a general breakdown in tolerance, but rather a more intricate expansion of selective autoreactive B cells and antibodies.

Indexed as

AdultAgedAntibodies, Anti-IdiotypicAntibodies, NeutralizingAutoantibodiesB-LymphocytesCD4 Lymphocyte Countenv Gene Products, Human Immunodeficiency VirusFemaleHIV-1HIV AntibodiesHIV InfectionsHumansImmune ToleranceImmunophenotypingMaleAntibodies, Anti-IdiotypicAntibodies, NeutralizingAutoantibodiesenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID22530008
PMCPMC3329433
OpenAlexW2003489482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.